The insider sales are routine and non-informative given the small proportional size and the CEO's single transaction. Monitor for any upcoming clinical catalysts or earnings that could move the stock, but this cluster does not warrant a bearish read-through. The strong institutional accumulation and bullish analyst consensus support a neutral near-term outlook.
IRON drugs
IRON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 27 $82.55entry
- T+1 · 3mo ago −3.05%α −2.83% · $80.03
- T+5 · 3mo ago −3.85%α −4.12% · $79.37
- T+20 · 8w ago −19.52%α −19.01% · $66.44
- T+56 · todayOpen
- T+60 · in 3d Pending
Price Chart
How similar events traded
Executive Summary
Two C-suite insiders at Disc Medicine (IRON) sold a total of $681K in open-market sales over a one-week window, with CEO John Quisel selling $656K and COO Jonathan Yu selling $25K. Yu also exercised and sold shares from options at ~$83, near the stock's current price. The cluster is modest relative to the $3.2B market cap (~0.02%), and the sales are likely liquidity-driven given the CEO's single large sale and the COO's option-exercise pattern, not a bearish signal on fundamentals. The company has a 95% bullish analyst consensus and strong institutional accumulation, suggesting the insider activity is routine and non-informative.
Key Financial Metrics
Key Facts
- CEO John Quisel sold 8,400 shares for $656K on 2026-08-17.
- COO Jonathan Yu sold 300 shares for $25K on 2026-08-24, following option exercises.
- Total open-market sales of $681K represent ~0.02% of IRON's $3.2B market cap.
- Yu's sales are part of a typical option-exercise-and-sell pattern, not a standalone bearish signal.
- Institutional ownership is strong with Fidelity, BlackRock, and Ra Capital as top holders, and recent 13F shows 9 adds and 5 doubled positions.
Financial Impact
Total insider sales of $681K, or ~0.02% of market cap, immaterial relative to company size.
Risk Factors
- Insider sales, while small, could precede a broader sell-off if negative clinical data emerges.
- The stock is in the pharmaceutical sector, where binary trial results can cause large moves independent of insider activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IRON-1787789468488 |
Track record
43 reports on IRON
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers